VEGF and VEGFR1 Gene expression levels predict tumor recurrence in adjuvant colon cancer Yan Ning1, Georg Lurje1, Kathleen Danenberg2, Janine Cooc2, Dongyun.

Slides:

Advertisements

Similar presentations

Cedars Sinai Medical Center

Advertisements

Advances and Emerging Therapy for Lung Cancer

Mizutomo Azuma 1, Michael M. Shi 2, Christian J. Jacques 2, Carl Barrett 2, Kathleen D. Danenberg 3, Syma Iqbal 1, Anthony El-Khoueiry 1, Dongyun Yang.

Introduction Materials and Methods Results Conclusions CD133 Polymorphisms are associated with clinical outcome in metastatic colorectal cancer (mCRC)

Introduction Patients and Methods Results Conclusion Wnt signaling is essential for embryonic development, stem cells and tissue regeneration. Colorectal.

KRAS is mutated in about 40% of colorectal cancers; it is the only validated predictive marker used in patients with metastatic CRC 1. It is also a negative.

References 1.Salazar R, Roepman P, Capella G et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J.

Novel Colon Cancer Tumor Suppressor Gene, Defensin-β1, Predicts Recurrence in Patients with Stage II and III Colon Cancer. Melissa J. LaBonte 1/2, Pierre.

Kerrington Smith, M.D. CTOS Nov 14, 2008

Cathy Eng M.D., Salil Sethi M.D., George J.Chang, M.D., Miguel A. Rodriguez-Bigas, M.D., John M. Skibber, M.D., Jianjun Shen Ph.D., Jijiang Zhu Ph.D.,

Insert Program or Hospital Logo Introduction Melanoma is notoriously resistant to chemotherapy. While surgical resection and adjuvant chemotherapy can.

A Micro RNA Polymorphism (MiRSNP) in 3’UTR of K-ras gene was associated with clinical outcome in mCRC patients treated with either single agent cetuximab.

Mizutomo Azuma 1, Dongyun Yang 2, Marinella Carpanu 3, Ellen Hollywood 3, Michael Lue-Yat 3, Wu Zhang 1, Kathleen D. Danenberg 4, Peter V. Danenberg 5,

Prospective study of EGFR intron 1 CA tandem repeats as predictive factor of benefit from cetuximab and irinotecan Antoniotti C 1, 2, Loupakis F 3, Cremolini.

Guanylyl Cyclase C (GCC) Lymph Nodes (LN) Classification as a Prognostic Marker in Patients with Stage II Colon Cancer: A Pooled Analysis Daniel J. Sargent,

ICAM-1, GRP-78 and NFkB gene polymorphisms associated with clinical outcome in patients with metastatic colorectal cancer treated with first line 5-FU.

Introduction Results Material and Methods Conclusions Genetic variants predict clinical outcome clinical outcome in patients (pts) with metastatic colorectal.

Cancer Stem Cell SNPs Have Opposite Prognostic Outcome in Patients with Gastric Cancer Among Asian and Western Countries Melissa J. LaBonte 1, Takeru Wakatsuki.

Gene Expression Signatures for Prognosis in NSCLC, Coupled with Signatures of Oncogenic Pathway Deregulation, Provide a Novel Approach for Selection of.

Clinical variables, pathological factors, and molecular markers for enhanced soft tissue sarcoma prognostication G. Lahat, B. Wang, D. Tuvin, DA. Anaya,

GOG0172: The Dings The recommended regimen is not feasible –Substitution of carboplatin for cisplatin –Reduce cisplatin from 100 mg/m 2 to 75 mg/m 2 –Change.

Intratumoral mRNA expression of genes involved in angiogenesis and HIF-1 pathway to predict outcome to VEGFR tyrosine kinase inhibitor (TKI) in patients.

CHFR METHYLATION AS AN EPIGENETIC MARKER FOR RECURRENCE OF COLON CANCER M. D. Anderson Cancer Center, Houston, Texas Motofumi Tanaka, Salil Sethi, Donghui.

Transcription Factor 7-like 2 (TCF7L2) Polymorphism Was Associated with Worse Survival in Three Independent Cohorts from the USA, Austria, and Japan Rita.

Introduction Patients and Methods Results Conclusion Pericytes are a key component in the maturation of the VEGF driven tumor angiogenic process 1. Bevacizumab.

The Influence of Age on Morbidity in Primary High Grade Sarcoma of the Extremity K. Alektiar, M. Brennan, S. Singer Memorial Sloan-Kettering Cancer Center.

Scott Kopetz, MD, PhD Department of Gastrointestinal Medical Oncology

Introduction Patients and Methods Results Conclusion Table 1. Baseline characteristics of the 108 patients included in the biomarker analysis. Objectives.

IntroductionPatient baseline characteristics Conclusion The process of EGFR recycling is important mechanism of resistance of cetuximab in colorectal cancer.

Pharmacogenetic analysis in metastatic colorectal cancer (mCRC) patients treated with second-line irinotecan (IR)+/- cetuximab (CB): The EPIC experience.

Chips? SNPs? or PCR? What do we really want and what do we need? Heinz-Josef Lenz, MD Professor of Medicine Co-Director, Colorectal Center Co-Director,

종양혈액내과 R4 고원진 / pf. 김시영 Rectal cancer : state of the art in 2012 Curr Opin Oncol 2012, 24:441–447.

R2 김재민 / Prof. 정재헌 Journal conference 1.

Patient & tumor characteristics (n=39)

Mamounas EP et al. Proc SABCS 2012;Abstract S1-10.

Figure 1. Raw mean scores of the MFI subscales ‘mental fatigue’ and ‘reduction in motivation’ (range 4–20, the higher the score the more mental fatigue.

COMBINATION OF CSF PROTEIN BIOMARKERS AND BDNF, IL10 AND IL6 GENOTYPES IN EARLY DIAGNOSIS OF ALZHEIMER’S DISEASE Mirjana Babić Leko1, Matea Nikolac Perković2,

University of Southern California, Norris Comprehensive Cancer Center

Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in Postmenopausal Women with Node-Positive, Estrogen- Receptor-Positive Breast Cancer.

Colorectal Cancer Update Patient Perspectives on Colorectal Cancer

Volume 15, Pages (February 2017)

Effect of microRNA-135a on Cell Proliferation, Migration, Invasion, Apoptosis and Tumor Angiogenesis Through the IGF-1/PI3K/Akt Signaling Pathway in Non-Small.

Prognosis of younger patients in non-small cell lung cancer

Predictive Biomarkers for Lung Cancer

Marcelo Calil Instituto Brasileiro de Controle do Câncer

Which Adjuvant Systemic Treatments Would Medical Oncologists Wish to Receive If They Had Colon Cancer? A Survey of 150 Physicians N Love, MD1; NJ Meropol,

USC/Norris Comprehensive Cancer Center

Lecture 11 By Shumaila Azam

Impact of Formal Methods in Biology and Medicine

Matrix-Degrading Metalloproteinases in Photoaging

Impact of Formal Methods in Biology and Medicine

Volume 133, Issue 6, Pages (December 2007)

Colon Cancer Stages I-III

Genetic variants of kinases suppressors of Ras (KSR)in KRAS-BRAF

Characterization of microRNA transcriptome in tumor, adjacent, and normal tissues of lung squamous cell carcinoma Jun Wang, MD, PhD, Zhi Li, MD, PhD,

Transcriptional Signature of Histone Deacetylases in Breast cancer

Volume 117, Issue 4, Pages (October 1999)

Robyn P. Hickerson, Sancy A. Leachman, Lana N

Published online September 20, 2017 by JAMA Surgery

Primary side of origin affects the outcome of mCRC patients treated with first-line FOLFIRI plus bevacizumab independently of BRAF status and mucinous.

Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials E Mitry, A Fields,

Treated with Neoadjuvant Therapy

KSR1 gene polymorphism in mCRC patients treated with first-line FOLFIRI and bevacizumab Marta Schirripa1, Fotios Loupakis1, Chiara Cremolini1, Dongyun.

- EVALUATION OF ISOLATION AND ANALYSIS SYSTEM FOR CTCS.

Supplementary Figure S1

Expression pattern of TLR-4 and MyD88 in EOC cells.

DO NOT POST #4054 Gene expression Difference (GED) Revealed Immune Function Gene UP- or Down-regulation as Tumor-associated Inflammatory Cell (TAIC) Infiltration.

624. Randomized Phase II Trial of Adjuvant Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer: Preliminary Results Molecular.

Presentation transcript:

VEGF and VEGFR1 Gene expression levels predict tumor recurrence in adjuvant colon cancer Yan Ning1, Georg Lurje1, Kathleen Danenberg2, Janine Cooc2, Dongyun Yang1, Alexandra Pohl1, Wu Zhang1, and Heinz-Josef Lenz1 1.USC/Norris Comprehensive Cancer Center, Los Angeles, CA 2. Response Genetics, Inc. Los Angeles, CA Introduction Results Tumor recurrence after curative resection is still a major problem in the management of adjuvant colon cancer, with recurrence rate approximately 30-40%. Identifying molecular markers for tumor recurrence is critical for successfully selecting patients who are more likely to benefit from adjuvant chemotherapy. Our group previously showed that angiogenesis gene polymorphisms (VEGF and IL-8) may associated with tumor recurrence in adjuvant colon cancer (Lurje Ann Oncol, 2008). Here we tested the hypothesis whether gene expression levels of angiogenesis pathway (COX-2, EGFR, VEGF, VEGFR1, VEGFR2 and IL-8) could also predict the risk of tumor recurrence in stage II and III colon cancer patients treated with adjuvant chemotherapy. Figure 2. high VEGFR1 mRNA levels associated with high tumor recurrence risk in adjuvant colon cancer Patients and method Figure 1. high VEGF mRNA levels associated with high tumor recurrence risk in adjuvant colon cancer Tissue samples from 140 adjuvant colon cancer patients (69 females and 71 males with a median age of 59 years; range=28-86) were available for gene expression assays. These tissue samples were obtained at the University of Southern California/Norris Comprehensive Cancer Center (USC/NCCC) and LAC+USC medical center between 1999 and 2006. Sixty-three patients had stage II and 77 had stage III colon cancer. The median follow-up was 5.4 years (range=2.0-16.8). 51 of 140 patients (36.4%) developed tumor recurrence with a 5-year probability of 0.28 ± 0.06 for stage II and 0.40 ± 0.06 for stage III colon cancer patients. mRNA was extracted from laser-capture-microdissected tumor tissue. After cDNA was prepared by reverse transcription, quantitation of the candidate genes and an internal reference gene (ß-actin) was performed using a fluorescence-based real-time detection method (TaqMan®). Primers and probes for the target gene was described previously. (Azuma, pharmacogenomics, 2007; Vallbohmer, JCO, 2005) Conclusion VEGF and VEGFR1 gene expression levels may predict tumor recurrence risk in adjuvant colon cancer patients. Our exploratory data warrant future confirmatory trial..